Vandetanib，又称凡德他尼，是可口服的VEGFR2抑制剂，IC₅₀为40 nM，作用于VEGFR3和EGFR的IC₅₀分别为110 nM 和500 nM，临床上常用于晚期甲状腺髓样癌的治疗。

参考文献

[1] Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002 Aug 15;62(16):4645-55(IF:8.378).

[2] Hegedüs C, Truta-Feles K, Antalffy G, et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol. 2012 Aug 1;84(3):260-7.  doi: 10.1016/j.bcp.2012.04.010(IF:4.825).

[3] Inoue K, Torimura T, Nakamura T, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Clin Cancer Res. 2012 Jul 15;18(14):3924-33. doi: 10.1158/1078-0432.CCR-11-2041(IF:8.911).

-25~-15℃保存，有效期3年。